Drug Approval | October 31, 2022
USFDA issues Form-483 for Lupin's Nagpur Unit-2
The company is committed to addressing the observations at the earliest, and gaining approval for injectable manufacturing for the US
The company is committed to addressing the observations at the earliest, and gaining approval for injectable manufacturing for the US
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
Indigenously-developed molecular diagnostics have helped expand the reach of diagnosis to every part of the country today
It allows users to generate cell lines suitable for clinical development without their own starter cells, vectors or prior experience in the field.
The JUMP-CP Consortium’s aim is to validate and scale up image-based drug discovery strategies by creating the world’s largest public cell imaging data set
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
Results reinforce commitment to next-generation oral SERD development programme
Frazier led the company for 10 years as President and Chief Executive Officer, from 2011 through 2021.
Oncodesign Services (ODS ), with 600 clients in 33 countries and 227 employees worldwide, provides services from target identification to hit-to-lead and lead optimization through to IND filing.
Subscribe To Our Newsletter & Stay Updated
